Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
FDA approves first direct-to-consumer test for breast cancer risk
Federal regulators approved the first direct-to-consumer test for the BRCA genes, which increase the risk of breast and ovarian cancer, the agency announced on Tuesday.
Prescription opioids fail rigorous new test for chronic pain
СHICAGO — A yearlong study offers rigorous new evidence against using prescription opioids for chronic pain.
Diabetes should be grouped into five types, rather than two, to tailor early treatment, researchers say
Cluster analysis of data from patient groups reveals that diabetes is more complex than the currently identified type 1 and type 2 diabetes.
Experimental HIV antibody successfully suppresses virus for six months: Study
An experimental HIV antibody has successfully suppressed the deadly virus for six months without additional treatment, a trial in monkeys has found.
Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis
ALPHARETTA, Ga.
Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH
Pratteln, Switzerland, March 5, 2018 - Santhera Pharmaceuticals (SIX.
Mylan to launch 2 HIV treatments
Mylan will soon be bringing its recently approved HIV medications Symfi Lo and Cimduo to market.
Management Board initiates building approval process for EMA premises in Amsterdam
The European Medicines Agency’s (EMA) Management Board met today in an extraordinary session to further discuss the building approval process for EMA’s future premises in Amsterdam, the Ne...
Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets
March 5, 2018, San Diego, CA – Vividion Therapeutics, Inc.
IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease
CARLSBAD, Calif.
Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)
EXTON, Pa.
BIAL and WhanIn signed an Exclusive Licensing Agreement for Zebinix in South Korea
February 27th, 2018 - BIAL and WhanIn Pharm.
455
456
457
458
459
460
461
462
463
